Showing 1-4 of 4 results for "


Annemiek Broyl et al.
The Lancet. Oncology, 11(11), 1057-1065 (2010-09-25)
Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity in patients with multiple myeloma, often requiring adjustment of treatment and affecting quality of life. We investigated the molecular profiles of early-onset (within one treatment cycle) versus late-onset (after two or three treatment...
Helena W Rodbard et al.
The lancet. Diabetes & endocrinology, 2(1), 30-37 (2014-03-14)
We compared stepwise addition of bolus insulin with a full basal-bolus regimen in patients with type 2 diabetes inadequately controlled on basal insulin plus oral antidiabetic drugs. The FullSTEP study was a phase 4, 32-week, randomised, open-label, two-arm, parallel-group, multinational...
Karim Fizazi et al.
The Lancet. Oncology, 15(13), 1442-1450 (2014-12-03)
Poor prognosis germ-cell tumours are only cured in about half of patients. We aimed to assess whether treatment intensification based on an early tumour marker decline will improve progression-free survival for patients with germ-cell tumours. In this phase 3, multicentre...
Alex Iranzo et al.
The Lancet. Neurology, 10(9), 797-805 (2011-08-02)
Serial dopamine transporter (DAT) imaging in patients with Parkinson's disease (PD) and other synucleinopathies shows progressive nigrostriatal dopaminergic dysfunction. Because idiopathic rapid-eye-movement (REM) sleep behaviour disorder (IRBD) can precede the classic symptoms of PD and other synucleinopathies, we postulated that...